We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
OGT Launches Cytocell FISH Probe for Bladder Cancer
Product News

OGT Launches Cytocell FISH Probe for Bladder Cancer

OGT Launches Cytocell FISH Probe for Bladder Cancer
Product News

OGT Launches Cytocell FISH Probe for Bladder Cancer


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "OGT Launches Cytocell FISH Probe for Bladder Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford Gene Technology has launched its CE-IVD labelled Cytocell Aquarius® P16/3c/7c/17c Probe Kit, a cost-effective, ready-to-use fluorescence in situ hybridisation (FISH) probe kit for non-invasive detection of bladder cancer — for sale in Europe.

Bladder cancer is becoming increasingly prevalent, and in 2012 was reported as the 5th most common cancer in Europe. While cytology screening is commonplace for diagnosing bladder cancer, a recent update to UK NICE guidelines recommended the use of FISH. FISH methods have been shown to have the same specificity as cytology screening and greater sensitivity in detecting bladder cancer cells. FISH analysis for bladder cancer is also particularly useful for monitoring treatment outcome and can aid in reducing patient mortality by detecting bladder cancer recurrence up to six months earlier than other methods.

Carrying the CE mark for in vitro diagnostic use within Europe, OGT’s product accurately detects in urine samples the three most common aneuploidies associated with bladder cancer (chromosomes 3, 7 and 17). It also detects deletions of the 9p21.3 locus containing the well-known tumour suppressor gene p16 (CDKN2A) — commonly deleted in bladder cancer. The economical Cytocell Aquarius P16/3c/7c/17c Probe Kit contains ready-to-use reagents and has an easy-to-use protocol, reducing the potential for errors and increasing convenience. Specific, clear, high-intensity signals with minimal background deliver quality, reproducible and easy-to-score results ensuring clinicians can be confident in reporting.

1508OGT06Oct OGT launches Cytocell FISH probe for bladder cancer.jpg

Dr. Lorenza Pecciarini, cytogeneticist at the Saint Raphael Hospital in Milan, who extensively tested the probe on a large series of samples, commented: “We found Cytocell’s bladder cancer probe kit easy to use, with bright results that were simple to interpret. It was straightforward to incorporate into our existing cytology workflow and was highly reproducible. This product offers an accurate and cost-effective technology for the diagnosis of bladder cancer.”

Martin Lawrie, Managing Director at Cytocell said: “The decision to expand OGT’s cancer portfolio and specifically Cytocell pathology probes, demonstrates OGT’s commitment to the fight against cancer. Supported by recent guidelines, our new bladder cancer probe kit delivers a convenient means to confident diagnoses, backed by the great customer support that OGT has become renowned for.”

Advertisement